Literature DB >> 11583632

Involvement of PIAS1 in the sumoylation of tumor suppressor p53.

T Kahyo1, T Nishida, H Yasuda.   

Abstract

Sumoylation of p53 by the ubiquitin-like protein, SUMO-1/sentrin/PIC1, has been shown to stimulate its transcriptional activation activity. The SUMO E3 ligase, a key enzyme in the recognition of substrates to be sumoylated, has not yet been identified. We isolated PIAS1 (protein inhibitor of activated STAT1) as a SUMO-1 binding protein by yeast two-hybrid screening. In addition, PIAS1 bound p53 and Ubc9, the E2 for SUMO. PIAS1 that was mutated in the RING finger-like domain bound p53 and SUMO-1, but not Ubc9. PIAS1 catalyzed the sumoylation of p53 both in U2OS cells and in vitro in a domain-dependent manner. These data suggest that PIAS1 functions as a SUMO ligase, or possibly as a tightly bound regulator of it, toward p53.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583632     DOI: 10.1016/s1097-2765(01)00349-5

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  152 in total

1.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

2.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Authors:  Darja Schmidt; Stefan Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 3.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

4.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

5.  A conserved catalytic residue in the ubiquitin-conjugating enzyme family.

Authors:  Pei-Ying Wu; Mary Hanlon; Michael Eddins; Colleen Tsui; Richard S Rogers; Jane P Jensen; Michael J Matunis; Allan M Weissman; Allan M Weisman; Allan M Weissman; Cynthia Wolberger; Cynthia P Wolberger; Cecile M Pickart
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

6.  Histone sumoylation is associated with transcriptional repression.

Authors:  Yuzuru Shiio; Robert N Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

7.  Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta.

Authors:  María Isabel Tussié-Luna; Dashzeveg Bayarsaihan; Edward Seto; Frank H Ruddle; Ananda L Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

8.  DNA cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation.

Authors:  Masamichi Ishiai; Masayo Kimura; Keiko Namikoshi; Mitsuyoshi Yamazoe; Kazuhiko Yamamoto; Hiroshi Arakawa; Kazunaga Agematsu; Nobuko Matsushita; Shunichi Takeda; Jean-Marie Buerstedde; Minoru Takata
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73.

Authors:  Eliana Munarriz; Daniela Barcaroli; Anastasis Stephanou; Paul A Townsend; Carine Maisse; Alessandro Terrinoni; Michael H Neale; Seamus J Martin; David S Latchman; Richard A Knight; Gerry Melino; Vincenzo De Laurenzi
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  PIAS1 inhibited the metastasis of gastric cancer cell by epithelial-mesenchymal transition regulation within the inflammatory microenvironment.

Authors:  Xiaoyu Wang; Libing Wang; Yan Xu; Guohua Zhang; Yunlin Wu; Ping Chen
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.